The projected or actual share price has moved upward. Early estimates forecast an IPO at $15-17 a share, while the final IPO finally priced at $19 a share. Rising above that, the market opened at $27 a share, and during Day One, shares rose as high as $33.
Market cap was $1.6B according to one trade journal (here). I believe that's at the nominal $19 per share price. That market cap value compares favorably to the circa $550M invested so far.
Guardant Health received Medicare coverage for its liquid biopsy gene panel test this past summer (here), for lung cancer patients.
|Click to enlarge: Yahoo Finance screen shot|